Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics (Adv. Mater. 45/2024)
Tumor Immunotherapy The cover depicts a large, often fatal, liver tumor receiving a percutaneously injected OG. The inset demonstrates the release of OG from the needle-tip with circumferential spread of the ionic liquid causing tumor ablation and inflammation with Nivolumab released from OG interacting with T-cells for immunotherapy. More details can be found in article number 2406080 by Rahmi Oklu and co-workers. Image credit: Mike Austin.
Authors
- Şeyda Gündüz (ORCID: https://orcid.org/0000-0002-6658-6345)
- Hassan Albadawi (ORCID: https://orcid.org/0000-0001-5913-8571)
- Zefu Zhang (ORCID: https://orcid.org/0000-0002-7916-6147)
- Enes Çevik (ORCID: https://orcid.org/0000-0002-1240-6150)
- Hirohito Kita (ORCID: https://orcid.org/0000-0002-6854-2936)
- Rahmi Öklü (ORCID: https://orcid.org/0000-0003-4984-1778)
- Hyeongseop Keum (ORCID: https://orcid.org/0000-0001-6680-5838)
- Bolni Marius Nagalo (ORCID: https://orcid.org/0000-0002-2173-7912)
Institutions
- WinnMed (US)
- Istinye University (TR)
- Mayo Clinic in Arizona (US)
- Liv Hospital (TR)
- University of Arkansas for Medical Sciences (US)
Publication Details
- Journal
- Advanced Materials
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/adma.202470363
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00